Summary
Big Pharma leaders embrace GLP-1s as longevity drugs as debate grows on what this means for patients, pipelines and policy.
At the twelfth Aging Research and Drug Discovery meeting (ARDD) in Copenhagen, the air was heavy with expectation; the conference has long been a forum where academia, biotech…
Source: Longevity.Technology
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
